Providing Oligonucleotides with Steric Selectivity by Brush-Polymer-Assisted Compaction.

Area of Science:

• Biotechnology
• Nanotechnology
• Pharmaceutical Sciences

Background:

• Oligonucleotides face challenges like poor enzymatic stability, rapid clearance, and immunostimulation, limiting their therapeutic use.
• These side effects often stem from interactions between oligonucleotides and proteins.

Purpose of the Study:

• To develop a novel brush-polymer/DNA conjugate to improve oligonucleotide biopharmaceutical properties.
• To investigate the role of conjugate structure in modulating protein interactions and therapeutic efficacy.

Main Methods:

• Synthesized novel brush-polymer/DNA conjugates.
• Evaluated hybridization kinetics with complementary DNA.
• Assessed protein interactions and adhesion.
• Studied the impact of brush side chain and DNA strand lengths on selectivity.
• Analyzed in vivo biodistribution.

Main Results:

• The developed conjugates exhibit nanoscale steric selectivity, preserving DNA hybridization kinetics.
• Protein interactions with DNA were significantly retarded by the brush-polymer structure.
• The length ratio of brush side chains to DNA strands critically influences selectivity.
• Evasion of protein adhesion led to improved in vivo biodistribution.

Conclusions:

• Brush-polymer/DNA conjugates represent a promising strategy for overcoming oligonucleotide therapeutic limitations.
• These nanostructures offer enhanced stability, reduced immunogenicity, and improved biodistribution for oligonucleotide-based therapies.
• The design of these conjugates allows for tunable control over therapeutic performance.